CoRegen, Inc.
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies (NCT07730125) | CoRegen, Inc. | 2026-11-01 |
Track CoRegen, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.